Pfizer Exits ViiV Healthcare as Shionogi Doubles Stake in $2.13 Billion Deal
Japan’s Shionogi & Co is paying $2.13 billion for new shares in ViiV Healthcare, increasing its stake from 10% to 21.7%.123
Pfizer is exiting its 11.7% stake in ViiV Healthcare, receiving approximately $1.88-$1.89 billion, with ViiV canceling its shares.123
GSK retains its 78.3% majority stake and will receive a $250 million special dividend.123
The deal simplifies ViiV's ownership structure and supports advancement of long-acting injectable HIV treatments and prevention medicines.123
Announced on January 20, 2026, the transaction is expected to close in Q1 2026, subject to regulatory approvals.34
Sources:
1. https://wtvbam.com/2026/01/20/japans-shionogi-boosts-viiv-stake-in-2-13-billion-deal-as-pfizer-exits/
2. https://www.pharmaceutical-technology.com/news/shionogi-expands-viiv-healthcare-stake-by-2-13bn-as-pfizer-sells-up/
3. https://www.indiapharmaoutlook.com/news/pfizer-exits-viiv-healthcare-in-19b-deal-shionogi-boosts-stake-nwid-4754.html
4. https://news.europawire.eu/shionogi-increases-stake-in-viiv-healthcare-to-21-7-percent-as-shareholder-structure-simplifies/eu-press-release/2026/01/20/13/41/42/168245/